This program is designed for director and vice president level management in the Life Science Industry. Participants complete the course with a certificate from the University of California Berkeley, Haas School of Business, Center for Executive Development.
Videos
"In addition to the course itself, the BioExec Institute provided an opportunity to engage in one-on-one conversations with leaders in various aspects of the industry that I would not otherwise have had the opportunity to meet." "
"I scoured websites of major business schools in search of a program that would provide an overview of the biopharma industry. The BioExec Program was the only program I came across and it is essentially everything I was looking for in an executive program."
“Attending this Institute gives you the strategies and the networks to operate and succeed at the next level in your organization.”
“The BioExec Institute was exceptional in the quality of the speakers and content that were provided. I would recommend this program to anyone interested in learning strategically about the Biotech industry.”
In the past five years, the BioExec Institute has brought together close to 400 Participants coming from companies such as:| Abgenix Achaogen, Inc. Act One Marketing Aemtek Aerovance Affymetrix AIDS Research Alliance Alder BioPharmaceuticals Allergan Inc Alvine Pharmaceuticals Alza Corp. Ambrx Amgen Amylin Pharmaceuticals Anadys Pharmaceuticals Applied Genetic Technologies Corp. Applied Materials, Inc. Arcturus Inc. Bathgate Capital Partners Baxter Bay City Capital BayBio BD BioScience Berlex Laboratories BIO BioAnalytics Marketing BioCrossroads Biodesix, Inc. BioMarin Pharmaceutical Inc. BioScience Forum BioTrove, Inc Blood Systems Research Institute Blue Shield of California Boston Scientific Corporation British Consulate-General Capgemini CardioVascular BioTherapeutics Chiron Corporation; CHORI City of Vacaville Consulate General of Canada Cooley Godward LLP Daiichi Sankyo Inc. Defense Technology Analysts Deloitte & Touche Deloitte Recap Deutsche Bank Development Economic Western Switzerland DuPont EBD Group EGeen International Corporation Epitomics Ernst & Young Eureka Therapeutics Executive Impact Group Exelixis Fenwick & West Flanders Investment and Trade Fliesler Meyer LLP ForteBio Fortune Capital Partners GE Healthcare Genentech, Inc. Genomic Health, Inc Geraldine Brush Cancer Research Institute GIRUS Life Sciences GlaxoSmithKline Plc GlobeImmune |
Guava Technologies, Inc. Healogix Health Strategies Group Hewlett Packard Hoag Cancer Center Ikonisys, Inc. IMS Health Intel Life Sciences Intuit Invencor Jazz Pharmaceuticals Johnson & Johnson KAI Pharmaceuticals Kaiser Permanente KDH Systems Kereos Inc. Lawrence Livermore National Laboratory LifeScan, Inc. Life Sciences Business Innovation Light House Capital Partners Locus Pharmaceuticals M-Squared Merck & Co. Inc. Merck Research Laboratories Metastorm Multispan Inc Nano Nerve nanoPharmatix Nanopoint, Inc. National Cancer Institute (NCI) National Development Fund of Taiwan National Genetics Institute NASA NeoDiagnostic Labs, Inc. Nile Therapeutics Novartis Pharmaceuticals Nuvelo Nycomed Odyssey Thera Onyx Pharmaceuticals Origen Therapeutics Orrick Emerging Companies OsteoCorp., Inc. Pain Therapeutics, Inc. Patheon Inc Pharmatech Associates, Inc. PHYSIC Ventures, LLC Poniard Pharmaceuticals, Inc. Quantum Consulting LLC Quorum Consulting Proteolix Roche San Jose BioCenter San Jose State University SARcode Sandia National Laboratories Siemens Medical Solutions Single Cell Technology Sonus Pharmaceuticals Spectrum Pharmaceuticals Squire, Sanders, & Dempsey LLP Stanford Licensing Group Stanford University Stanford Medical Center State of California US Venture Partners XOMA Ltd. |